* Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in regions outside the United States, Canada and Japan
The post BRIEF-Exelixis and Ipsen enter into exclusive licensing agreement appeared first on NASDAQ.